A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group, 2-arm Study to Investigate the Safety and Immunogenicity of a 4-dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers
Latest Information Update: 10 Mar 2025
Price :
$35 *
At a glance
- Drugs SP-0202 (Primary) ; Hib-DTaP-hepatitis B-poliovirus vaccine; Measles mumps and rubella virus vaccine; Measles mumps and rubella virus vaccine; Pneumococcal 20-valent conjugate vaccine; Rotavirus W179-9 vaccine; Varicella zoster virus vaccine live; Varicella zoster virus vaccine live
- Indications Pneumococcal infections
- Focus Pharmacodynamics; Registrational
- Sponsors Sanofi Pasteur
- 22 Dec 2024 Status changed from not yet recruiting to recruiting.
- 16 Dec 2024 Status changed from planning to not yet recruiting.
- 04 Jul 2023 New trial record